Jpmorgan Chase & CO Aim Immuno Tech Inc. Call Options Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding AIM

# of Institutions
5
Shares Held
699K
Call Options Held
0
Put Options Held
0
View Full List

About AIM ImmunoTech Inc.

AIM Quotes by TradingView
  • Ticker AIM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,049,300
  • Market Cap $122M
  • Description
  • AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...
More about AIM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email